Skip to main content
Log in

In Vitro and in Vivo Evaluation in Rabbits of a Controlled Release 5-fluorouracil Subconjunctival Implant Based on Poly(D,L-lactide-co-glycolide)

  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

Abstract

Purpose. To design a controlled release 5-fluorouracil (5-FU) implant to provide prolonged antifibroblast concentrations of 5-FU in the sub-conjunctival tissues but low concentrations of 5-FU in other ocular tissues.

Methods. Implants (5 mg; 2.5 mm diameter × 1.2 mm thickness) of 5-FU or 9:1, 8:2, 7:3 5-FU to polymer mass ratios were made by compression. Poly(D,L-lactide-co-glycolide) polymers with 50:50 and 75:25 lactide to glycolide ratios were used. In vitro release characteristics of four types of implants were studied: 5-FU alone (CT), 5-FU/ polymer matrices (MT), coated 5-FU/polymer matrices with a central hole drilled through the matrix and coating (CM1), and with a central hole in the coating (CM2). MT and CM1 (9:1 drug/polymer) were selected for subconjunctival implantation in rabbits. 14C-5-FU levels in various ocular tissues and retrieved pellets were monitored.

Results. First-order release was observed from CT, MT and CM1 implants. Zero-order release profiles were observed from CM2 implants. Drug release was retarded by formulating 5-FU in a matrix comprising poly(D,L-lactide-co-glycolide) which in turn could be modified by the lactide/glycolide ratio of the polymer, the drug to polymer ratio, coating, and hole dimensions. First-order release kinetics were observed for MT and CM1 implants in the in vivo study in rabbits. A correlation between in vitro and in vivo release was established which allowed in vivo release to be predicted from in vitro release data. For CM1, therapeutic tissue concentrations of 35.2 µg/g (conjunctiva) and 17.7µLg/g (sclera) were found at the implantation site up to 200 hours post-implantation. Tracer levels were undetectable in other ocular tissues.

Conclusions. The CM1 implant maintained steady antifibroblast levels in target tissues and minimized levels in nontarget tissues.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. D. K. Heuer, R. K. I. Parrish, M. G. Gressel, E. Hodapp, P. F. Palmberg, and D. P. Anderson. 5-fluorouracil and glaucoma filtering surgery II: A pilot study. Ophthalmol. 91:384–394 (1984).

    Google Scholar 

  2. M. G. Gressel, R. K. I. Parrish, and R. Folberg. 5-fluorouracil and glaucoma filtering surgery: I. An animal model. Ophthalmol. 91:378–383 (1984).

    Google Scholar 

  3. A. Ophir and U. Ticho. Encapsulated filtering bleb and subconjunctival 5-fluorouracil. Ophthalmic Surg. 23:339–341 (1992).

    Google Scholar 

  4. B. Wolner, J. M. Liebmann, J. W. Sassani, R. Ritch, M. Speaker, and M. Marmor. Late bleb-related endophthalmitis after trabeculectomy with adjunctive 5-fluorouracil. Ophthalmol. 98:1053–1060 (1991).

    Google Scholar 

  5. R. N. Weinreb. Adjusting the dose of 5-fluorouracil after filtration surgery to minimise side effects. Ophthalmol. 94:564–570 (1987).

    Google Scholar 

  6. A. Ophir and U. Ticho. Toxic effect of 5-fluorouracil on fibroblasts following trabeculectomy. Ophthalmic Res. 24:298–302 (1992).

    Google Scholar 

  7. D. A. Lee, P. Hersh, D. Kersten, and S. Melamed. Complications of subconjunctival 5-fluorouracil following glaucoma filtering surgery. Ophthalmic Surg. 18:187–190 (1987).

    Google Scholar 

  8. N. Nao-i and Y. Honda. Toxic effect of fluorouracil on the rabbit retina. Am. J. Ophthalmol. 96:641–643 (1983).

    Google Scholar 

  9. P. T. Khaw, S. Ward, A. Porter, I. Grierson, R. A. Hitchings, and N. S. Rice. The long-term effects of 5-fluorouracil and sodium butyrate on human Tenon's fibroblasts. Invest. Ophthalmol. Vis. Sci. 33:2043–2052 (1992).

    Google Scholar 

  10. B. K. Lowe. Personal communication with Birmingham Polymers, Inc. Birmingham, USA (1995).

  11. C. Chiang and R. D. Schoenwald. Ocular pharmacokinetic models of clonidine-3H hydrochloride. J. Pharmacokinet. Biopharm. 14:175–211 (1986).

    Google Scholar 

  12. J. G. Wagner. Interpretation of percent dissolved-time plots derived from in vitro testing of conventional tablets and capsules. J. Pharm. Sci. 58:1253–1257 (1969).

    Google Scholar 

  13. M. Gibaldi and S. Feldman. Establishment of sink conditions in dissolution rate determinations: theoretical considerations and application to nonodistingrating dosage forms. J. Pharm. Sci. 56:1238–1242 (1967).

    Google Scholar 

  14. R. D. Purves. A macintosh application for non-linear parameter estimation. Department of pharmacology, University of Otago, Dunedin, 1992.

    Google Scholar 

  15. K. Yamaoka, T. Nakagawa, and T. Uno. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J. Pharmacokinet. Biopharm. 6:165–175 (1978).

    Google Scholar 

  16. G. L. Skuta and R. K. I. Parrish. Wound healing in glaucoma filtering surgery. Surv. Ophthalmol. 32:149–170 (1987).

    Google Scholar 

  17. E. J. Rockwood, P. K. Parrish, D. K. Heuer, G. L. Skuta, E. Hodapp, P. F. Palmberg, M. G. Gressel, and W. Feuer. Glaucoma filtering surgery with 5-fluorouracil. Ophthalmol. 94:1071–1078 (1987).

    Google Scholar 

  18. S. T. Simmons, M. B. Sherwood, D. A. Nichols, R. B. Penne, T. Sery, and L. Spaeth. Pharmacokinetics of a 5-fluorouracil liposomal delivery system. Br. J. Ophthalmol. 72:688–691 (1988).

    Google Scholar 

  19. I. Finkelstein, G. E. Trope, J. G. Heathcote, D. S. Rootman, L. Spero, and I. A. Menon. Further evaluation of collagen shields as a delivery system for 5-fluorouracil: histopathological observations. Can. J. Ophthalmol. 26:129–132 (1991).

    Google Scholar 

  20. T. J. Smith, M. B. Maurin, S. M. Milosovich, and A. Hussain. Polyvinyl alcohol membrane permeability characteristics of 5-fluorouracil. J. Ocul. Pharmacol. 4:147–152 (1987).

    Google Scholar 

  21. P. E. Rubsamen, P. A. Davis, E. Hernandez, G. E. O'Grady, and S. W. Cousins. Prevention of experimental proliferative vitreoretionopathy with a biodegradable intravitreal implant for the sustained release of fluorouracil. Arch. Ophthalmol. 112:407–413 (1994).

    Google Scholar 

  22. M. S. Hora, R. K. Rana, J. H. Nunberg, T. R. Tice, R. M. Gilley, and M. E. Hudson. Release of human serum albumin from poly(-lactide-co-glycolide) microspheres. Pharm. Res. 7:1190–1194 (1990).

    Google Scholar 

  23. R. A. Siegel. Modelling of drug release from porous polymers. In M. Rosoff (ed), Controlled Release of Drugs: polymer and aggregate systems, VCH Publishers Inc., New Youk, 1989, pp. 1–52.

    Google Scholar 

  24. D. Brooke and R. J. Washkuhn. Zero-order drug delivery system: theory and preliminary testing. J. Pharm. Sci. 66:159–162 (1977).

    Google Scholar 

  25. D. S. Hsieh, W. D. Rhine, and R. Langer. Zero-order controlled-release polymer matrices for micro-and macromolecules. J. Pharm. Sci. 72:17–22 (1983).

    Google Scholar 

  26. D. S. Mishra and S. H. Yalkowsky. A flat circular hole device for zero-order release of drugs: characterisation of the moving dissolution boundary. Pharm. Res. 7:1195–1197 (1990).

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wang, G., Tucker, I.G., Roberts, M.S. et al. In Vitro and in Vivo Evaluation in Rabbits of a Controlled Release 5-fluorouracil Subconjunctival Implant Based on Poly(D,L-lactide-co-glycolide). Pharm Res 13, 1059–1064 (1996). https://doi.org/10.1023/A:1016062825360

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1016062825360

Navigation